ABUS vs CHTR · P/E 5.4, rev $6.2M vs P/E 11, rev $55.09B
Arbutus Biopharma Corp (ABUS) versus Charter Communications Inc (CHTR) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Charter Communications Inc (CHTR) is a telecom services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CHTR revenue for 2024-12-31 was $55.09B. Net income was $5.85B. Revenue was up 0.9% from 2023-12-31 to 2024-12-31. CHTR currently screens at market cap $56.24B and trailing P/E 11.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CHTR currently screens at market cap $56.24B and trailing P/E 11.5.
Not investment advice. Open the ABUS and CHTR stock pages for the full models.
Not investment advice.